Table 1.
Characteristics of bosutinib-treated patients (n = 13).
| No | Age at dg. | Sex (f/m) | Arm | Sokal risk group | BCR-ABL IS% at dg. | BCR-ABL IS% at 3m | BCR-ABL IS% at 12m |
|---|---|---|---|---|---|---|---|
| Bo1 | 46 | f | Bosutinib | Inter. | 107,8 | 3,1 | 0,029 |
| Bo2 | 32 | f | Bosutinib | High | 16,9 | 0,008 | neg |
| Bo3 | 30 | m | Bosutinib | Low | 82,0 | 1,51 | 0,0016 |
| Bo4 | 42 | f | Bosutinib | Inter. | 99,6 | 21,36 | switched to Im |
| Bo5 | 62 | f | Bosutinib | High | 77,9 | 20,04 | switched to Im |
| Bo6 | 54 | m | Bosutinib | Inter. | 93,88 | 0,26 | 0,0086 |
| Bo7 | 35 | f | Bosutinib | Low | 74,9 | 0,15 | neg |
| Bo8 | 77 | f | Bosutinib | Inter. | 24,2 | switched to Im | switched to Im |
| Bo9 | 28 | f | Bosutinib | Low | 98,1 | 7,98 | 0,019 |
| Bo10 | 30 | m | Bosutinib | Low | 19,6 | 0,20 | discontinued |
| Bo11 | 60 | f | Bosutinib | Inter. | 92,5 | 16,9 | 0,012 |
| Bo12 | 52 | m | Bosutinib | Inter. | 76,7 | 1,22 | 0,049 |
| Bo13 | 62 | f | Bosutinib | Low | 79,0 | discontinued | discontinued |
| Median [range] |
46 [28–77] |
Male, 31% |
Low 38% Inter. 46% High 15% |
79 [16,9–107,8] |
1,51 [0,008 − 21,36] |
0,01042 [neg −0,049] |
Abbreviations: dg, diagnosis; f, female; Im, Imatinib; Inter., intermediate; IS, international scale; m, male.